Ever Fortune.AI announced on the 2nd an investment of NT$329 million to participate in the seasoned equity offering of its subsidiary, EverBot Technology. Post-investment, EFAI's stake will rise from 46.45% to 50.01%, granting it operational control.

• Medical Robotics: EFL’s "AIBO," Taiwan's first mass-produced generative AI medical care robot, enters production this quarter (Q1 2026), with a target of 200 units by year-end. EFL plans to list on the Emerging Stock Board in H2 2026.
• Regulatory Success: EFAI's Seg Pro V3 (Radiotherapy Organ Auto-Contouring System) has received U.S. FDA 510(k) clearance. Notably, it is the first in its category (QKB) globally to pass the FDA's Predetermined Change Control Plan (PCCP), a significant regulatory milestone for AI software.

Resource: 長佳智能 擬參與長聯現增